The registry’s research includes efforts to define optimal therapy regimens for PPB and DICER1-related cancers and to discover new therapies for DICER1-related cancers, develop new ways to diagnose children with DICER1-related cancers and present surveillance guidelines for patients with germline DICER1 mutations [16]. This evidence concerns the gene DICER1 and pleuropulmonary blastoma.